April 25, 2017 04:27 AM EDT

With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact

Arsalan Arif

Founder

Five months after Amgen and Novartis outlined their second batch of positive Phase III data for their CGRP migraine drug erenumab, the two giants have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact

Arsalan Arif

Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO

With late-stage da­ta in on the CGRP mi­graine drug erenum­ab, No­var­tis and Am­gen re­work com­mer­cial­iza­tion pact

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO